Member Info for EmeraldCarrots

If not already one or more major investors will be looking at buying a significant stake considering all the recent good news.

All IMHO.

Save Scotland’s NHS almost £20,000,000 over five years. More one presumes if that is extended to 6,7,8,9 years etc...

So, what method to use?

The lab method or Genedrive's machine?

Lab method needs a blood draw. Then the sample needs to get to the lab. If the lab is in the hospital as one presumes some are then the result might be back later same day if you are lucky. If the lab is 50 miles away, then one presumes we are talking days before the result is received. No good at all.

Genedrive method. No blood draw, just cheek swab. Result in around an hour. Cheaper unless the lab is testing numerous samples at the same time which seems highly unlikely. Also, the Genedrive reactive agents can be stored at room temperature, so no freezer needed for storage.

There is no comparison. The Genedrive machine wins hands down with ease.

All IMHO.

Also NICE have already recommended Genedrives's use for the whole UK NHS for "point of care".

All IMHO.

To what SHTD's conclusion is (see page 40) than your own personal interpretation of the report which seems incredibly negative and bias. From the reports CONCLUSION on page 40:-

"The results of our cost analysis for Scotland found that implementing laboratory-based genotype-

guided antiplatelet therapy would be resource saving in the first year. Point of care genotype testing

was cost incurring in the first year. Resource savings associated with reduced recurrent stroke rates

were greater than the ongoing costs associated with each strategy of genotype testing from year 2

onwards. Over 5 years, all testing strategies were associated with significant resource savings of

around £17.8 million.".

Note "ALL TESTING STRATEGIES".

All IMHO.

Group (SHTG).

1. **Laboratory-based genotype-guided antiplatelet therapy was resource saving from the year of implementation. Over a 5-year period, -----resource savings amounted to £17.9 million------, based on 943 fewer people having a recurrent stroke.

2. **Point of care genotype testing was cost incurring in the year of implementation and from year two onwards became resource saving. Over a 5-year period, the Genedrive point of care test was associated with

***---------£18 million in resource savings and 961 fewer recurrent strokes.-------***

Over the same period, the Genomadix Cube point of care test was associated with resource savings of £17.6 million, based on 958 fewer people having a recurrent stroke."

- Over 5 years Genedrive is cheaper. Not only that it's portable, gives the result in about an hour and does not need a blood draw. There is NO CONTEST. The market simply can't ignore this for long.

- Sp likely to rocket after this excellent news.

https://shtg.scot/our-advice/clopidogrel-genotype-testing-after-ischaemic-stroke-or-transient-ischaemic-attack-tia/

In case you missed it:-

Https://www.proactiveinvestors.co.uk/search/advancedSearch/all?keyword=ANGLE+PLC

Happen then? Why else would they close?

They can still do a non RNS announcement. If they were not privy to the details before the SHTD news (which is fantastic) they would have needed time to read it and evaluate it's implications for sales to the Scottish NHS.

Maybe later today. Lots of people have contected them I think.

All IMHO.

Maybe due to distances involved................................

**Laboratory-based genotype-guided antiplatelet therapy was resource saving from the year of implementation. Over a 5-year period, -----resource savings amounted to £17.9 million------, based on 943 fewer people having a recurrent stroke.

**Point of care genotype testing was cost incurring in the year of implementation and from year two onwards became resource saving. Over a 5-year period, the Genedrive point of care test was associated with

***---------£18 million in resource savings and 961 fewer recurrent strokes.-------***

Over the same period, the Genomadix Cube point of care test was associated with resource savings of £17.6 million, based on 958 fewer people having a recurrent stroke."

- Over 5 years Genedrive is cheaper. Not only that it's portable, gives the result in about an hour and does not need a blood draw. There is NO CONTEST.

- Sp is going to rocket here after this.

https://shtg.scot/our-advice/clopidogrel-genotype-testing-after-ischaemic-stroke-or-transient-ischaemic-attack-tia/

How can GDR not highlight the this report that basically says the Genedrive machine is CHEAPER in Scotland than the lab test! This makes the machine a "must have" IMHO.

Maybe due to distances involved................................

**Laboratory-based genotype-guided antiplatelet therapy was resource saving from the year of implementation. Over a 5-year period, resource savings amounted to £17.9 million, based on 943 fewer people having a recurrent stroke.

**Point of care genotype testing was cost incurring in the year of implementation and from year two onwards became resource saving. Over a 5-year period, the Genedrive point of care test was associated with £18 million in resource savings and 961 fewer recurrent strokes. Over the same period, the Genomadix Cube point of care test was associated with resource savings of £17.6 million, based on 958 fewer people having a recurrent stroke."

- Over 5 years Genedrive is cheaper. Not only that it's portable, gives the result in about an hour and does not need a blood draw. There is NO CONTEST.

- Sp is going to rocket here after this.

https://shtg.scot/our-advice/clopidogrel-genotype-testing-after-ischaemic-stroke-or-transient-ischaemic-attack-tia/

Days IMHO.

Stroke machine:-

https://shtg.scot/our-advice/clopidogrel-genotype-testing-after-ischaemic-stroke-or-transient-ischaemic-attack-tia/

Babies hearing one:-

Https://shtg.scot/our-advice/genotype-testing-to-guide-antibiotic-use-and-prevent-hearing-loss-in-babies/

NHS Scotland "in the bag" I think!!!

I think they should do a "non RNS" announcement to say that they are happy with the SHTG report for Scotlands NHS. They should be delighted as it says using the Genedrive machine in Scotlands NHS would be CHEAPER over 5 years than the hospitals lab option. Plus as we know the lab option can take days AND needs a blood draw. Genedrives maching does the test in about an hour and you don't have a blood draw (cheek swab sample). No competition. See "Advice" document, page 3.

"Our cost analysis for NHSScotland found that genotype-guided antiplatelet therapy was resource saving compared with no testing, resulting from a reduction in-hospital and rehabilitation costs associated with fewer people having a recurrent stroke.

**Laboratory-based genotype-guided antiplatelet therapy was resource saving from the year of implementation. Over a 5-year period, resource savings amounted to £17.9 million, based on 943 fewer people having a recurrent stroke.

**Point of care genotype testing was cost incurring in the year of implementation and from year two onwards became resource saving. Over a 5-year period, the Genedrive point of care test was associated with £18 million in resource savings and 961 fewer recurrent strokes. Over the same period, the Genomadix Cube point of care test was

associated with resource savings of £17.6 million, based on 958 fewer people having a

recurrent stroke."

https://shtg.scot/our-advice/clopidogrel-genotype-testing-after-ischaemic-stroke-or-transient-ischaemic-attack-tia/

GloriaMarket.

The report is more positive than the NICE one, which was also positive. Basically using Genedrive's machine for the test over 5 years would be slightly CHEAPER than using the "lab" option which involves a blood draw and a long wait for the result (possibly days). No blood draw needed for Genedrives machine (cheek swab), no long wait (only about an hour). In effect it's a glowing endorsement for using Gendrive's machine without promoting the machine in a way that might get them accused of bias. The market will love this once the news has sunk in. The SHTG report is very good.

All IMHO.

https://shtg.scot/our-advice/clopidogrel-genotype-testing-after-ischaemic-stroke-or-transient-ischaemic-attack-tia/

Harrizma.

"Seems like the newsflow is about to commence. NHS Scotland will take this on as save a fortune it seems. No brainer. Bring it on. 10-20p target here".

=================

Reading the full version of the SHPD report it becomes obvious they know the Genedrive machine is the best option, even though they do not precisely say that. Worried about repercussions of recommending I suspect. GDR will know this too.

All IMHO.

https://shtg.scot/our-advice/clopidogrel-genotype-testing-after-ischaemic-stroke-or-transient-ischaemic-attack-tia/

"Our cost analysis for NHSScotland found that genotype-guided antiplatelet therapy was resource saving compared with no testing, resulting from a reduction in-hospital and rehabilitation costs associated with fewer people having a recurrent stroke. o Laboratory-based genotype-guided antiplatelet therapy was resource saving from the

year of implementation.

***Over a 5-year period, resource savings amounted to £17.9million, based on 943 fewer people having a recurrent stroke.***

Point of care genotype testing was cost incurring in the year of implementation and

from year two onwards became resource saving.

***Over a 5-year period, the Genedrive point of care test was associated with £18 million in resource savings and 961 fewer recurrent strokes. Over the same period, the Genomadix Cube point of care test was associated with resource savings of £17.6 million, based on 958 fewer people having a recurrent stroke.***."

=====================

So over 5 years the Genedrive machine £100,000 cheaper and 961 fewer recurrent strokes as opposed to the lab's 943 fewer. Thank you SHTD!

All IMHO.

If you look carefully! Easy to miss. Says Genedrive's machine, over 5 years is slightly cheaper than taking a blood sample and sending it off to a lab which is obviously more work, more dangerous (infections?) and can take days!!!!!!!!!

Sp zooming back now. Was down 8%, now only 3.5%.

All IMHO.

Was associated with £18 million in resource savings and 961 fewer recurrent strokes. ". Nice!!!!!

file:///C:/Users/PROQU/Downloads/20241030-clopidogrel-assessment-v10.pdf

Duggs999.

"Best news would be SHTG guidance to roll out the Genedrive machine in all Scottish hospitals. Cost of creating new labs with expensive lab staff is far more prohibitive than putting local capacity in place and training a local trainer in each hospital. Performing the test in each hospital would be part of the nurses day job as it is so quick and simple and therefore zero extra labour costs. It really is win/win/win for the patient and the NHS.".

============================

It seems to me there are three main issues with getting a lab test instead of using Genedrives machine.

1. Usually takes a few days. Genedrive's machine takes about an hour.

2. Needs a blood draw (GEnedrive's machine does NOT). Any blood draw must add risk of infection.

3. Lab test more expensive.

The case for adopting Genedrive's machine seems obvious. It will be interesting to find out what SHTG's opinion is later TODAY.

https://shtg.scot/our-advice/

All IMHO.

Box. Keep 'em peeled!!

https://shtg.scot/our-advice/